Physician profile
Mathew Benjamin
NPI 1699891614
$17,124.86
in general payments reported to CMS, 2019-2025
57 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,373 · 2020: $1,547 · 2021: $2,076 · 2022: $2,591 · 2023: $2,519 · 2024: $2,258 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,507 · Education: $31.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,506.94 |
| Education | $31.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,578.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,600.54 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $1,449.18 | 2021-2025 | |
| Abbvie INC. | $1,413.90 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $796.94 | 2019-2025 | Spravato |
| Allergan, INC. | $720.01 | 2019-2020 | |
| Lilly USA, LLC | $688.33 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $553.93 | 2019-2025 | Repatha, Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $502.61 | 2023-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $468.65 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $425.49 | 2020-2021 | |
| Abbott Laboratories | $409.65 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $388.35 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $372.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $330.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.